Navigation Links
NeurogesX Reports Third Quarter 2008 Results
Date:11/6/2008

pectively. The weighted average shares used in computing loss per share attributable to common stockholders exclude anti-dilutive securities such as stock options and warrants.

Cash, cash equivalents and short-term investments were approximately $30.8 million as of September 30, 2008, compared to $38.0 million at June 30, 2008.

Stephen Ghiglieri, CFO, commented, "In this difficult financial market, we are dedicating our financial resources primarily to obtain marketing approvals for NGX-4010. By pursuing this focused strategy, we believe our existing cash resources are sufficient to move us through expected regulatory decisions in both the U.S. and Europe, and potentially into early 2010. Our objective is to ensure an effective launch of NGX-4010, if approved, in both Europe and the United States. We intend to achieve this through effective cost management, including a near-term focus on activities for NGX-4010 that support the ongoing regulatory review processes and our reimbursement strategies and through commercial partnerships and other non-equity sources of funding. In addition, we anticipate that these other sources of funding could create opportunities to more rapidly advance our development initiatives in addition to effectively launching NGX-4010 in the United States. Given the current state of the equity markets, we have no current intention to raise equity capital in the public markets."

Clinical Development Update

NeurogesX' near-term clinical focus is to secure regulatory approvals of the NDA and MAA for NGX-4010. Regarding the potential for additional clinical studies in HIV-DSP and/or PDN, NeurogesX continues to evaluate the appropriate scope and nature of future studies, if any, in these indications. The timing for initiating such studies will be based in part on availability of financial resources.

NGX-1998, the Company's second-generation, liquid formulation of high-concentration capsaicin (10% trans-capsaicin) is
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. NeurogesX to Present at BioCenturys NewsMakers in the Biotech Industry Conference
2. NeurogesX Appoints New Director to the Board
3. NeurogesX to Present at UBS 2007 Global Life Sciences Conference
4. NeurogesX Expands Senior Management Team
5. NeurogesX to Present at CIBC World Markets 18th Annual Healthcare Conference and Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. NeurogesX to Present at Lazard Capital Markets Healthcare Conference
7. NeurogesX, Inc. Announces $25 Million Private Placement
8. NeurogesX Closes $25 Million Private Placement
9. NeurogesX to Present at the 10th Annual BIO CEO & Investor Conference
10. NeurogesX to Present at Roth 2008 OC Growth Stock Conference
11. NeurogesX to Report Fourth Quarter and Year-End 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... MA (PRWEB) January 22, 2015 zFlo ... is pleased to announce an exciting product from a new ... motion analysis solutions over the past 15 years, with offerings ... Most recently, their 3D IMU system (inertial measurement unit), iSen, ...
(Date:1/22/2015)... 2015 Selexis SA, a serial innovation ... Banks (RCBs) used for drug discovery to commercial manufacturing, ... include Next-Generation Sequencing (NGS) data packages. The ... manufacturing by ensuring the integrity of the gene, validation ...
(Date:1/22/2015)... Jan. 22, 2015   Cypher Genomics, Inc., ... (NASDAQ: SQNM ), the leading molecular ... next generation noninvasive prenatal tests (NIPT). Through this ... called Mantis™, to advance analysis of clinically-relevant fetal ...
(Date:1/22/2015)...  Derma Sciences, Inc. (Nasdaq: DSCI ), ... care, announces that AMNIOEXCEL® and AMNIOMATRIX®, amniotic allografts ... the Premier, Inc. Regenerative Skin Grafting contract portfolio. ... and AMNIOMATRIX® product lines, which continue to be ...
Breaking Biology Technology:3D Motion Capture Just Got Easy 2Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5
... LIVERPOOL, February 2 Gray Healthcare has ... to lead its,expanding Community Recovery Team, as Clinical Director. ... years, experience of senior management in mental,health in both the ... of operations at Cambian Healthcare, covering 12 psychiatric,rehabilitation hospitals, he ...
... SAN DIEGO , Feb. 1 BioMed Realty Trust, Inc. ... its fourth quarter and year ended December 31, 2009 after ... Alan D. Gold , Chairman and Chief Executive Officer, and ... conference call at 10:00 a.m. Pacific Time on Thursday, ...
... Astrogenetix ... Space Station (ISS) to 2020 or beyond. , ... (Vocus) February 1, 2010 -- Astrogenetix is issuing the following statement applauding ... beyond. , ,Thomas B. Pickens III, Chairman of Astrogenetix, Inc.:, , ,“We are excited to ...
Cached Biology Technology:Noel Tracey to Head Up Gray Healthcare Recovery Team 2BioMed Realty Trust to Report 2009 Fourth Quarter and Year-End Results 2Astrogenetix Statement On Nasa's Fiscal Year 2011 Budget Announcement 2
(Date:12/17/2014)... Dec. 16, 2014 Valencell, a leader in performance ... technology to industry leaders such as Intel, Jabra, Atlas, ... biometric wearable products. These products will be showcased at ... Las Vegas . "Our partners ...
(Date:12/11/2014)... , Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition of the ... to their offering. One major trend ... continuous advances in technology, it is important to upgrade ...
(Date:12/10/2014)... YORK , Dec. 8, 2014 You,ve been here before: ... can,t remember your password, site key or the answer to your ... teacher? Today, Hoyos Labs , a digital ... put an end to the frustration that comes with usernames, passwords ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3
... existed in the Amazon before the arrival of Europeans, ... the result of research led by Crystal McMichael and ... The finding overturns the idea the Amazon was a ... that transformed vast tracts of the landscape. The ...
... vegetarian and ecological products, but is it really making ... about ethical trade, Gothenburg researchers Bengt Brlde and ... help ease people,s bad conscience, it does nothing to ... fixing the problem will require collective solutions, such as ...
... UC Santa Barbara scientists turned to the simple sponge to ... and found that, but for a mechanism that coordinates the ... synapses, sponges and the rest of the animal world may ... of a protosynaptic gene expression network," are published in the ...
Cached Biology News:Scientists reconstruct pre-Columbian human effects on the Amazon Basin 2Ethical trade: 'Good intentions go to waste' 2Clues to nervous system evolution found in nerve-less sponge 2
... Polyclonal Phosphorylated Anti-GluR1 Glutamate is the ... many years it had been considered to ... NMDA, AMPA and kainate receptors that are ... Recently, glutamate has been shown to regulate ...
Anti-ADP-Ribosylation Factor 1, clone 3F1 Immunogen: Synthetic peptide corresponding to the C-terminal amino acid sequence of human ARF1. Available Date: 38495...
TNF-Related Apoptosis Inducing Ligand-Receptor-1...
Pim-1 (12H8)...
Biology Products: